MedDataX Logo

Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response

NCT ID: NCT01534442

Last Updated: 2012-12-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the role of transmission of vagal cholinerg for the GLP-1 potentiation of the glucose stimulated insulin secretion and the cephalic insulin response by using atropin administration.

The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the investigators will research individuals with an intact nervous supply with and without atropin administration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

GLP-1 is a importent enterogastron and incretin hormone. Rapid degradation of GLP-1 by dipeptidyl peptidase 4 (DPP-4) suggests that GLP-1 may act locally (through vagal afferents) before being degraded. We aimed to clarify the role of vagal innervation on the incretin effect.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

The Focus of This Study is to Evaluete the Significances of the Vagal Cholinerg Nervuos System for the Effect of GLP-1 by Using Atropin Administration.

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atropin

Atropin

Group Type ACTIVE_COMPARATOR

Atropine

Intervention Type DRUG

1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.

Placebo

Saline

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atropine

1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age between 18 and 45 years
* normal fasting plasma glucose
* normal hemoglobin
* informed consent

Exclusion Criteria

* diabetes mellitus
* body mass index above 30
* inflamatoric bowel disease
* intestinal surgery
* serum creatinine above 250 microM
* ALAT above to times normal value
* treatment with medicine wich cannot be paused for 12 hours
* contraindication for treatment with atropin
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Copenhagen

OTHER

Sponsor Role collaborator

University Hospital, Gentofte, Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jonatan I Bagger

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tina Vilsbøll, MD, Dr. med

Role: STUDY_DIRECTOR

Diabetes research Division, Department of Internal Medicine, Gentofte Hospital, Copenhagen, Denamrk

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Diabetes research Division, Department of Internal Medicin, Gentofte Hospital

Hellerup, , Denmark

Site Status RECRUITING

Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, Copenhagen Denmark

Hellerup, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Astrid Plamboeck, MD

Role: CONTACT

Phone: + 45 26208174

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Astrid Plamboeck, MD

Role: primary

Tina Vilsbøll, MD, Dr. med

Role: backup

Astrid Plamboeck, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Veedfald S, Plamboeck A, Deacon CF, Hartmann B, Knop FK, Vilsboll T, Holst JJ. Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. Am J Physiol Gastrointest Liver Physiol. 2016 Jan 1;310(1):G43-51. doi: 10.1152/ajpgi.00222.2015. Epub 2015 Oct 22.

Reference Type DERIVED
PMID: 26492921 (View on PubMed)

Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Vilsboll T, Knop FK, Holst JJ. The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. Am J Physiol Regul Integr Comp Physiol. 2015 Sep;309(5):R544-51. doi: 10.1152/ajpregu.00123.2015. Epub 2015 Jul 1.

Reference Type DERIVED
PMID: 26136531 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Atropin clamp

Identifier Type: -

Identifier Source: org_study_id